Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
In 2014, an estimated 7,000 patients were diagnosed of melanoma in China. It is growing at an
annual rate of 3%-5% and approximately 20,000 new cases are reported each year recently.To
date, CFDA only approved dacarbazine as first line chemotherapy and anti-PD-1 antibody
monotherapy as second line. There is no standard of care after chemotherapy and anti-PD-1.